We are delighted to announce that our seminal paper A novel process driving Alzheimer’s validated in a mouse model: therapeutic potential’ has been accepted by the peer-reviewed journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions. At last, our disruptive approach to Alzheimer’s, proof of concept of our basic hypothesis, and efficacy of our novel drug NBP14, will have a wider public platform. We see this MS as a real milestone since it brings together previously disparate reports in the literature for mapping the steps in the neurodegenerative process and suggests a first-in-class drug treatment, now acknowledged by the MHRA as completely innovative. Although the manuscript is under embargo for 6 weeks, we are currently planning a press conference in early April. More details will be available as plans become clearer, but please watch this space!
LATEST NEWS
- Our Office Manager Charles Monro attended the new opening of the reception area at UK Atomic Energy Authority
- Neuro-Bio welcomes back Adam Khan
- Charles Munro, our Office Manager attends Culham Campus Quarterly Tenant lunch
- Neuro-Bio welcomes Amy Lewis
- New lateral flow test may detect Alzheimer’s decades early! In collaboration with Aptamer Group!